tiprankstipranks
ANGLE Inks Deal for Advanced Cancer Sequencing Tech
Company Announcements

ANGLE Inks Deal for Advanced Cancer Sequencing Tech

ANGLE plc (GB:AGL) has released an update.

Don't Miss our Black Friday Offers:

ANGLE plc has entered into an agreement with NuProbe to attain an exclusive license for a next-generation sequencing (NGS) assay, enhancing the capabilities of its liquid biopsy technology, Parsortix. The NGS panel, which facilitates the analysis of both circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) from a single blood sample, promises to advance cancer treatment personalization. This collaboration aims to bolster ANGLE’s pharma services and offer clinicians tools for ongoing monitoring of tumor dynamics and patient response to therapies.

For further insights into GB:AGL stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks UK Auto-Generated NewsdeskANGLE plc Showcases New HER2 Assay Developments
TipRanks UK Auto-Generated NewsdeskANGLE plc Showcases Innovative Liquid Biopsy for Cancer
TipRanks UK Auto-Generated NewsdeskANGLE plc Highlights Advances in Liquid Biopsy Technology
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App